CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLABO19

Thyroid Disease Testing

BCBSNM clinical payment and coding policy that defines reimbursement criteria for thyroid function and related laboratory testing for members covered under Blue Cross Blue Shield of New Mexico products. Applies to providers submitting claims for thyroid-related lab tests and describes when testing is reimbursable or not.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLABO19

Change TypeNew policy

Effective DateJan 1, 2023

Next Review Date

Key ActionProviders must submit accurate documentation supporting the clinical indication for thyroid testing (symptoms, high-risk conditions, pregnancy status, medication exposures, monitoring after therapy) when billing these tests.

SourceLink

POLICY UPDATE CHANGES

1/1/2023 - New policy implemented.

1.0policy version

2023-01-01plan effective date

1policy update entries

16+distinct clinical/reimbursement criteria sections (approx.)

When Thyroid Function Testing Is Reimbursable

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General reimbursement conditions for thyroid function testing

Thyroid function testing may be reimbursable when listed clinical indications or monitoring requirements are met. Not all requirements apply to each product.

Tests considered not reimbursable or limited

Specific tests and situations stated as not reimbursable except where exceptions are listed:

ANY of the following

Testing of reverse T3, T3 uptake and total T4 is not reimbursable in all situations except for total T4 in pregnancy management when FT4 trimester-specific ranges unavailable
Measurement of total T3 and/or free T3 is not reimbursable in the assessment of hypothyroidism
Measurement of total or free T3 level is not reimbursable when assessing levothyroxine (T4) dose in hypothyroid patients
Testing for thyroid dysfunction in asymptomatic nonpregnant individuals during general exam without abnormal findings is not reimbursable

What Providers Must Do

Documentation Required

Document clinical indication

Providers must submit accurate documentation that supports the clinical indication for thyroid testing (for example: symptoms, high-risk conditions, pregnancy status, medication exposures, monitoring after therapy) when billing listed thyroid laboratory tests.

84432
84437
84436
84479
84480
84481
84482
86376

Prior Authorization

Product-specific coverage may vary

Not all requirements in this policy apply to every BCBSNM product; providers should review the member's plan documents for eligible coverage and may be asked to provide additional documentation during claim review.

Denial Risk

Denial risk for screening in asymptomatic nonpregnant individuals

Claims for thyroid dysfunction testing in asymptomatic nonpregnant individuals during general examinations without abnormal findings are not reimbursable and are at risk for denial.

Documentation Required

Pregnancy lab selection requirement

When testing during pregnancy, laboratories must use trimester-specific reference ranges for FT4 assays; if trimester-specific FT4 ranges are unavailable, total T4 may be used per Note 1.

84436
84437

Clinical and Administrative Context

This policy defines BCBSNM's laboratory reimbursement criteria for thyroid function testing and aligns reimbursement with established clinical indications and monitoring needs. Coverage is intended to match testing to clinical presentation — for example, testing when there are symptoms of hypothyroidism or hyperthyroidism, when follow-up or secondary causes are suspected, for monitoring therapy, and for specified high-risk conditions and pregnancy-related management — rather than for routine population screening.

The policy identifies certain tests as low-value or not reimbursable in most situations. Specifically, reverse T3 and T3 uptake testing are listed as not reimbursable, and routine measurement of total T3 (or free T3) is not reimbursable for assessment of hypothyroidism or for routine assessment of levothyroxine dosing unless otherwise stated in policy exceptions.

The policy places particular emphasis on pregnancy-specific testing. It favors free T4 (FT4) for pregnancy management when laboratories have trimester-specific reference ranges, allows total T4 (TT4) only when FT4 trimester ranges are unavailable or discordant with TSH, and specifies more frequent monitoring for pregnant individuals treated for hypothyroidism (every 4 weeks).

Monitoring Intervals and Numeric Thresholds

Monitoring interval for hypothyroidism/hyperthyroidism after dose changeEvery 6–12 weeks after dosage change; annually in stable individuals

Pregnancy hypothyroidism monitoring intervalEvery 4 weeks when treated for hypothyroidism during pregnancy

Hyperthyroidism close monitoring windowFirst 3 months post treatment (close monitoring)

Morbid obesity definition used in pregnancy risk listBMI ≥ 40 kg/m2